Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ben Morris

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Neoplasia (New York, N.Y.)|October 28, 2025
Cholesterol biosynthesis as a drug-induced vulnerability in diffuse large B cell lymphoma insensitive to EZH2 inhibitionRachele Niccolai, Camiel Göbel, Klevis Ndoj, et al.
Cancer Immunology Research|February 8, 2023
Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic CellsEsmée P Hoefsmit, Paula T van Royen, Disha Rao, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2025
A functionally validated TCR-pMHC database for TCR specificity model developmentMarius Messemaker, Bjørn P Y Kwee, Živa Moravec, et al.
Blood|January 10, 2025
Targeting DOT1L and EZH2 synergizes in breaking the germinal center identity of diffuse large B-cell lymphomaCamiel Göbel, Rachele Niccolai, Marnix H P de Groot, et al.
Nucleic Acids Research|July 12, 2022
Division of labor within the DNA damage tolerance system reveals non-epistatic and clinically actionable targets for precision cancer medicineAldo Spanjaard, Ronak Shah, Daniël de Groot, et al.
Cell Reports. Medicine|March 20, 2024
Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapseMengnuo Chen, Sara Mainardi, Cor Lieftink, et al.
Nature|October 4, 2019
Inducing and exploiting vulnerabilities for the treatment of liver cancerCun Wang, Serena Vegna, Haojie Jin, et al.
Cell Reports|May 20, 2023
Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumorsJinhyuk Bhin, Mariana Paes Dias, Ewa Gogola, et al.
Medrxiv : the Preprint Server for Health Sciences|March 3, 2023
Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patientsTesa M Severson, Yanyun Zhu, Stefan Prekovic, et al.
Nature Communications|July 17, 2021
Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancerStefan Prekovic, Karianne Schuurman, Isabel Mayayo-Peralta, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Neoplasia (New York, N.Y.)|October 28, 2025
Cholesterol biosynthesis as a drug-induced vulnerability in diffuse large B cell lymphoma insensitive to EZH2 inhibitionRachele Niccolai, Camiel Göbel, Klevis Ndoj, et al.
Cancer Immunology Research|February 8, 2023
Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic CellsEsmée P Hoefsmit, Paula T van Royen, Disha Rao, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2025
A functionally validated TCR-pMHC database for TCR specificity model developmentMarius Messemaker, Bjørn P Y Kwee, Živa Moravec, et al.
Blood|January 10, 2025
Targeting DOT1L and EZH2 synergizes in breaking the germinal center identity of diffuse large B-cell lymphomaCamiel Göbel, Rachele Niccolai, Marnix H P de Groot, et al.
Nucleic Acids Research|July 12, 2022
Division of labor within the DNA damage tolerance system reveals non-epistatic and clinically actionable targets for precision cancer medicineAldo Spanjaard, Ronak Shah, Daniël de Groot, et al.
Cell Reports. Medicine|March 20, 2024
Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapseMengnuo Chen, Sara Mainardi, Cor Lieftink, et al.
Nature|October 4, 2019
Inducing and exploiting vulnerabilities for the treatment of liver cancerCun Wang, Serena Vegna, Haojie Jin, et al.
Cell Reports|May 20, 2023
Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumorsJinhyuk Bhin, Mariana Paes Dias, Ewa Gogola, et al.
Medrxiv : the Preprint Server for Health Sciences|March 3, 2023
Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patientsTesa M Severson, Yanyun Zhu, Stefan Prekovic, et al.
Nature Communications|July 17, 2021
Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancerStefan Prekovic, Karianne Schuurman, Isabel Mayayo-Peralta, et al.
Pageof 4